Axsome Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Axsome Therapeutics, Inc. stands as a biopharmaceutical firm dedicated to developing innovative treatments for central nervous system (CNS) conditions within the United States. The company’s portfolio features marketed products including Auvelity (dextromethorphan HBr and bupropion HCl extended-release tablets), approved for adults experiencing major depressive disorder, and Sunosi (solriamfetol) for addressing excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Additionally, Symbravo (meloxicam and rizatriptan) recently gained approval in early 2025 for the acute management of migraine with or without aura. Its advanced pipeline continues with AXS-05, currently under an sNDA review with the FDA for Alzheimer's disease agitation, and slated to commence a pivotal Phase 2/3 trial for smoking cessation in late 2025. The company is also progressing AXS-12, a selective norepinephrine reuptake inhibitor, with an NDA submission anticipated in late 2025 for narcolepsy, specifically to treat cataplexy. Another investigational medicine, AXS-14 (esreboxetine), is planned to enter Phase 3 trials for fibromyalgia in late 2025. Further expanding its therapeutic reach, Axsome recently acquired a subtype selective GABA-A receptor positive allosteric modulator for epilepsy in November 2025. The company, established in 2012, maintains its headquarters in New York, New York, focusing on delivering meaningful advancements in patient outcomes.
Company News
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Bank of America Corp DE Acquires Shares of 452,491 Axsome Therapeutics, Inc. $AXSM
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Is Axsome Therapeutics a Buy on the Dip?
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript